Bharat Biotech in Phase 3 data: Covaxin overall 77.8% effective

In a statement, Bharat Biotech claimed that the Covaxin is overall 77.8 per cent effective against Covid, citing the data from the third phase of clinical trials.

However, the data is yet to be peer-reviewed.

The vaccine maker said that it was also found to be “93.4 per cent effective” against severe symptomatic Covid-19.
“We are proud to put India on the global map with scientific conviction, competence and commitment. Covaxin scores 10 world-class publications endorsing Innovation, clinical research, data, safety, efficacy. Thank collaborators & Positive BB teamwork enduring a pandemic (sic),” Bharat Biotech co-founder Suchitra Ella said in a late-night tweet.

In a statement, the vaccine maker further said, “Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.”

“The safety profile of Covaxin is now well established based on inactivated vaccines technology, and in large part due to the extensive 20-year safety track record of Bharat Biotech’s vero cell manufacturing platform. Furthermore, Bharat Biotech has so far not sought indemnity for Covaxin from the governments,” it said.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “The successful safety and efficacy readouts of Covaxin as a result of conducting the largest ever Covid vaccines trials in India establishes the ability of India and developing world countries to focus towards innovation and novel product development. We are proud to state that Innovation from India will now be available to protect global population.”

“The successful development of Covaxin has consolidated the position of Indian academia and Industry in the global arena,” Prof. (Dr) Balram Bhargava, Secretary Department of Health Research & Director General Indian Council of Medical Research, said.